Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937)

This publication has 22 references indexed in Scilit:

• Agents that Down-Regulate or Inhibit Protein Kinase C Circumvent Resistance to 1-β-D-Arabinofuranosylcytosine-Induced Apoptosis in Human Leukemia Cells that Overexpress Bcl-2
  Molecular Pharmacology, 1997
• Modulation of Protein Kinase C Activity and Calcium-Sensitive Isoform Expression in Human Myeloid Leukemia Cells by Bryostatin 1: Relationship to Differentiation and Ara-C-Induced Apoptosis
  Experimental Cell Research, 1996
• Inactivation of Bcl-2 by phosphorylation.
  Proceedings of the National Academy of Sciences, 1995
• Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro
  Cancer Immunology, Immunotherapy, 1994
• Update on the Antitumor Activity of Paclitaxel in Clinical Trials
  Annals of Pharmacotherapy, 1994
• Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[β-d-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells
  Biochemical Pharmacology, 1994
• Premature p34 ^cdc2 Activation Required for Apoptosis
  Science, 1994
• Intracellular Signaling by Hydrolysis of Phospholipids and Activation of Protein Kinase C
  Science, 1992
• Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60.
  Proceedings of the National Academy of Sciences, 1986
• Taxol: an antimitotic agent with a new mechanism of action
  Pharmacology & Therapeutics, 1984